Thursday 19 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterprise solutionsVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

Gross margin is the number that turns a launch into a business

Revenue growth was easy to find in this earnings season. The companies that pair it with unit economics, as Delcath and Autolus have begun to, are the ones that will set their own terms.

18 Nov 2026 · CompePharma editorial

Growth is everywhere. Margin is not.

Read the third-quarter releases in sequence and the headline numbers blur together. Tonix reported TONMYA net sales of about $15 million, up 37% from the second quarter. Kura's KOMZIFTI grew 53% sequentially to $13.9 million. ADC Therapeutics booked $21 million in net product revenue. Autolus reported $41.2 million for AUCATZYL, up 95% year over year. Each is a launch moving in the right direction.

Growth of that kind now tells an executive very little, because nearly every commercial-stage company can produce it. The sharper question is what each incremental dollar of revenue costs to deliver. On that question the quarter separates companies more cleanly than any growth rate does.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →